HAVCR2 and colorectal cancer: The identification of increased levels of immune checkpoint expression, particularly of TIM3, CLTA‐4, and PD‐1, in MSI colorectal cancers that are well known for a high pre‐existing antitumor immunity underlines the concept that high levels of immune checkpoint expression do not hinder anticancer immunity in an inflamed TME.